close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

199.57 +1.09 (+0.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
NTRA Q2 Deep Dive: Oncology Growth, Product Innovation, and Margin Pressures
Genetic testing company Natera (NASDAQ:NTRA). reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 32.2% year on year to $546.6 million. The company’s full-year revenue... 
Via StockStory
Topics Artificial Intelligence
2 Mid-Cap Stocks on Our Watchlist and 1 We Brush Off
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
5 Analysts Have This To Say About Natera
 
Via Benzinga
1 of Wall Street’s Favorite Stock to Own for Decades and 2 We Turn Down
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
How Is The Market Feeling About Natera?
 
Via Benzinga
Earnings Scheduled For August 7, 2025
 
Via Benzinga
How Do Investors Really Feel About Natera?
 
Via Benzinga
Tech Stocks Eye Record Highs As Magnificent Seven Top $19.5 Trillion: What's Moving Markets Friday?
Tech stocks staged a full rebound from last Friday's sell-off, with the Nasdaq 100 surging to 23,600 — just shy of the 23,700 all-time high set in late July, as the week’s strong sector earnings and... 
Via Benzinga
Why Are Natera (NTRA) Shares Soaring Today
Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 11.6% in the morning session after it reported strong second-quarter 2025 financial results, including a significant revenue beat and... 
Via StockStory
Topics Earnings World Trade
SoundHound AI, Ouster, Globalstar, Doximity, JFrog And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Topics Artificial Intelligence
Natera (NASDAQ:NTRA) Delivers Strong Q2 Numbers, Stock Jumps 12.6%
Genetic testing company Natera (NASDAQ:NTRA). reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 32.2% year on year to $546.6 million. The company’s full-year revenue... 
Via StockStory
Natera NTRA Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Natera (NTRA) Q2 Revenue Jumps 32%
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
What To Expect From Natera’s (NTRA) Q2 Earnings
Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results this Thursday after market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Schlumberger, Stellantis And ASML Holding Are Among Top 10 Large Cap Losers Last Week (July 14-July 18): Are The Others In Your Portfolio?
Elevance Health and Waters led the weekly large-cap losers, hit by weak earnings, lowered guidance, and analyst downgrades. 
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
1 Unprofitable Stock for Long-Term Investors and 2 to Approach with Caution
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
1 Growth Stock with Exciting Potential and 2 to Be Wary Of
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)
Let’s dig into the relative performance of Natera (NASDAQ:NTRA) and its peers as we unravel the now-completed Q1 immuno-oncology earnings season. 
Via StockStory
Topics Artificial Intelligence
Here's How Much $100 Invested In Natera 10 Years Ago Would Be Worth Today
 
Via Benzinga
1 Volatile Stock to Own for Decades and 2 to Brush Off
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
3 Reasons We Love Natera (NTRA)
Natera has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 5% to $170 per share while the index has gained 1.1%. 
Via StockStory
Topics Government Stocks
Here's How Much You Would Have Made Owning Natera Stock In The Last 10 Years
 
Via Benzinga
A Look Back at Immuno-Oncology Stocks’ Q1 Earnings: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Pack
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase
Genetic testing company Natera (NASDAQ:NTRA). reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue... 
Via StockStory
9 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
2 Cash-Heavy Stocks for Long-Term Investors and 1 to Be Wary Of
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today